[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401867":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":39,"collaborators":7,"id":41,"slug":7,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Beijing 302 Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Cyberknife stereotactic body radiation therapy","A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Jing Sun","CONTACT","+8613718681094","519299998@qq.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Xuezhang Duan","+8613621386161","duanxuezhang2006@163.com",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Beijing 302 hospital","RECRUITING","Beijing","100039","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100401867",false,"NCT04512833","CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis","CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Primary HCC diagnosed by a surgeon and\u002For radiologist and oncologist according to the international guidelines for the management of HCC or by pathology\n* Unfeasible or refusing to undergo other treatments;\n* Residual normal liver volume ≥700 cc;\n* With decompensated cirrhosis (Child-Pugh B or C classification);\n* Without portal vein tumor thrombus;\n* Eastern Cooperative Oncology Group (ECOG) score 0-1;\n* Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm；\n* Rejecting other therapies such as resection, liver transplantation, etc.\n* Platelet count≥50 × 109\u002FL, white blood count≥1.5 × 109\u002FL;\n* Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.\n\nExclusion Criteria:\n\n* With Tumor thrombus；\n* With extrahepatic metastasis;\n* With lymph node involvement.","ALL","30 Years","80 Years",{"count":51,"type":52},60,"ESTIMATED","OBSERVATIONAL","The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.",[56],"Hepatocellular Carcinoma",[58,59,60,61,62],"hepatocellular carcinoma","CyberKnife","stereotactic body radiation therapy","Child-Pugh B classification","Child-Pugh C classification","2023-06-24",{"date":65,"type":66},"2023-06-27","ACTUAL",{"date":68,"type":66},"2020-08-12",{"date":70,"type":52},"2026-08-30",{"name":5,"class":6},1]